Sign in
Not yet taking people in United StatesNo phase

Blocking Stomach Artery to Test Weight Loss in Fatty Liver Disease

Tests blocking a stomach artery to help adults with obesity and NASH liver disease.

Key facts

Who runs it
Keith Pereira, MD:
Where
St Louis, United StatesSee the site
Trial code
Registry title
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
Status
Not yet recruiting
People taking part
8 people, planned
Started
Dec 2025
Expected to end
Jun 2027
Type of study
Interventional
Treatments tested
  • Embospheres Microspheres
Record updated
28 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 22 to 65 with obesity (BMI over 35) and biopsy-proven NASH (fatty liver with inflammation). It tests a blood-vessel block to the stomach (left gastric artery embolization) to help weight loss and improve NASH.

Age
22 to 65 years
Sex
All sexes can join.
Disease stage
NASH shown on a liver biopsy in the past 12 months, with raised liver enzymes (ALT over 41 or AST over 34 U/L) and BMI over 35 kg/m2. No other liver disease. Not decompensated liver disease and not Child Pugh C.
Earlier treatment
Must have tried diet, exercise and behavior changes for weight loss without success. Cannot have had weight loss surgery or earlier embolization of the stomach, spleen or liver (liver TACE for HCC is allowed). Aspirin and NSAIDs must be stopped at least 3 days before and for 30 days after the procedure.
Biomarker or test result
Elevated ALT (over 41 U/L) or AST (over 34 U/L). Blood counts, bilirubin under 3 mg/dL and kidney function (GFR over 60) must be adequate.

Main reasons for not taking part

  • Pregnancy
  • Active substance abuse or heavy alcohol use
  • Weight over 400 lbs or BMI over 50 kg/m2
  • Other causes of liver disease, such as hepatitis B or C
  • Metastatic cancer or decompensated liver disease

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Male or Female, aged 22 years or older
  • Willing, able and mentally competent to provide written informed consent and willing to comply with all study procedures and be available for the duration of the study
  • BMI >35 kg/m2
  • Adequate hematological, hepatic and renal function as follows:; Hematological: Hematological: If the bariatric embolization procedure is being performed by femoral access: platelets > 50 x 109/L, INR <1.5. If the bariatric embolization procedure is being performed by radial access: platelets >35 x 109/L and INR <1.5 OR platelets >50 x 109/L and INR between 1.5 and 2."; Hepatic : Total bilirubin <3 mg/dL; Renal: Estimated GFR > 60ml/min.1.73m2
  • If Center for Epidemiological Studies Depression (CESD) score > or =16 AND is in care of behavior health specialist who has indicated patient has adequate coping mechanisms to undergo procedure and does not foresee mental health as barrier to participation in study
  • Elevated alanine or aspartate aminotransferase values (ALT >41 or AST>34 U/L)
  • Liver biopsy showing evidence of NASH in the past 12 months
  • No evidence of another form of liver disease
  • Patients diagnosed with NASH and have evidence of failing other methods of weight loss through diet, exercise and behavior modification

Who cannot take part

  • Subjects requiring any anticoagulant medications should be excluded if radial access cannot be obtained
  • Subjects who are taking aspirin/ NSAIDs and in whom these medications are unable to be withdrawn from aspirin and NSAIDs for at least 3 days prior to the LGAE procedure and for 30 days following the LGAE procedure (because of the potential risks of gastric bleeding following the procedure)
  • prior surgical weight loss procedures including gastroplasty, jejunoileal, or jejunocolic bypass, total parenteral nutrition within the past 6 months; Prior history of gastric pancreatic, hepatic, and/or splenic surgery
  • Prior embolization to the stomach, spleen or liver, unless the prior embolization was a transarterial chemoembolization (TACE) to the liver for HCC
  • If review of available prior imaging studies (i.e CT, MRI, or US)shows potential anatomical variations, presence of severe atheromatous disease, large arteriovenous shunting of blood
  • Patient taking hepatotoxic drugs. List of drugs causing steatohepatitis include but are not limited to: amiodarone, chemotherapy (5-fluorouracil, tamoxifen, irinotecan, cisplatin, and asparaginase), glucocorticoids, methotrexate, sulfonamides, antithyroid drugs, phenytoin, tetracyclines, isoniazid, salicylates, and valproic acid
  • Patients taking other trial medications for NASH
  • Significant psychiatric problems, severe enough to cause suffering or a poor ability to function in life. Center for Epidemiological Studies Depression (CESD) score > or = 16 without psychiatric evaluation. [If Center for Epidemiological Studies Depression (CESD) score > or =16 AND is in care of behavior health specialist who has indicated patient has adequate coping mechanisms to undergo procedure and does not foresee mental health as barrier to participation in study.]
  • Presence of systemic illness or other medical conditions relevant to survival .(Note that in the HCC pre liver transplant cohort, the presence of HCC will not be considered an exclusion criteria)
  • Metastatic cancer
  • Evidence of decompensated liver disease (uncontrolled ascites, or uncontrolled spontaneous encephalopathy)
  • Abnormal Endoscopy - large sliding hiatal hernia or paraesophageal hernia, active peptic ulcer disease, active H. pylori infection
  • History of abnormal Nuclear Gastric Motility examination-defined as delayed emptying of gastric contents > 90%, 60% and 10% at 1 hour, 2 hours, and 4 hours respectively
  • Known aortic disease, such as dissection or aneurysm; peripheral arterial disease or other cardiovascular disease
  • Type 2 diabetes on anti-diabetic medications that are known to cause hypoglycemia. e.g. sulphonylureas, meglitinides
  • Patients with a known other cause for their increased liver enzyme levels such as viral hepatitis (B or C), autoimmune/chronic immune hepatitis, primary biliary cholangitis, metabolic and genetic hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency
  • Subjects with platelets <35 x 109/L and INR > 2.0
  • Pregnancy
  • Active substance abuse
  • Significant alcohol consumption ( >20 g/day in women, >30 g/day in men)
  • Weight > 400 lbs, BMI > 50 kg/m2
  • Contraindications to obtaining a liver biopsy
  • Subjects with pre-existing abdominal pain will be excluded (because of the potential confusion with pain related to the procedure)
  • Subjects who are intolerant to PPIs
  • ASA Class 4 or 5
  • Child Pugh classification C
  • Contraindications to obtaining a liver biopsy (NASH cohort)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 22 and 65 years old?

Where in United States

  • Saint Louis UniversitySt Louis, United StatesContact: Keith Pereira, MDNot yet recruiting

About the trial

What the trial wants to find out

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of progression of fibrosis in NASH is crucial, as they are at a high risk for cirrhosis and may need liver transplant.

Read full original descriptionShow less

Recent studies have shown that blocking blood vessels to a particular portion of the stomach (bariatric or left gastric artery embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and result in weight loss.The purpose of this study is to determine if Left gastric artery embolization (LGAE) in patients with obesity and NASH leads to clinically significant weight loss with improvement of NASH.

The group in the trial

  • NASH- Left gastric artery embolizationTreatment being tested

    Embospheres Microspheres as artificial embolic agent for left gastric artery embolization

    Treatment: Embospheres Microspheres

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH
Plain-language title
Blocking Stomach Artery to Test Weight Loss in Fatty Liver DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT02933554, who can take part
Record updated
28 July 2025